Buyers price a pharmacy on adjusted EBITDA: profit after adding back your own above-market compensation, family payroll, personal expenses run through the business, one-time costs, and any gap between the rent you pay yourself and market rent. Once that number is settled, most buyers sanity-check it against script volume and revenue per script, because those tell them whether the profit is durable. Prescription inventory is almost always valued separately at cost and added to the purchase price rather than being folded into the multiple, so an owner comparing two offers needs to know which structure each one is using before deciding which is higher.
The single biggest driver of where a pharmacy lands in its range is the quality of its reimbursement. A book weighted toward stable contracts and cash-pay or specialty business carries far less risk than one concentrated in a handful of plans with thin or shrinking margins. Buyers will model what happens to your profit if a major contract reprices, so the pharmacies that hold their multiple are the ones that can show several years of stable gross margin per script rather than a single strong year. Front-end retail sales, immunizations, compounding and adherence programs all help, because they diversify profit away from third-party reimbursement.
Two pharmacies with the same profit routinely sell at different multiples. The gap is risk. Buyers pay more when a second pharmacist already runs the day-to-day, when the lease has real term remaining and is assignable, when the software and records transfer cleanly, and when the books are clean enough that diligence does not turn into an argument. They pay less when the owner is the only pharmacist, when one plan or one prescriber drives a large share of volume, or when growth came from a source that will not repeat. None of this is visible in a calculator, which is why an online estimate is a starting point for a conversation rather than an answer.
Profit, in almost every case. Adjusted EBITDA is the basis for the multiple, and script count and revenue are used to test whether that profit is sustainable. A pharmacy filling a high volume of low-margin prescriptions can be worth less than a smaller one with better reimbursement, because the buyer is purchasing future earnings rather than turnover. Prescription inventory is normally paid for separately at cost, on top of the multiple of earnings.
They affect it through the multiple rather than the profit. Buyers assume reimbursement will keep tightening, so a pharmacy whose margin depends on one or two plans is underwritten more conservatively than one with a diversified payor mix and meaningful cash-pay, specialty or front-end revenue. Showing several consecutive years of stable gross margin per script is one of the most effective ways to defend your multiple.